Brought to you by 
AZ pays $240mm up front for mRNA collaboration with Moderna
Mar 2013
Executive Summary
Marking the largest up-front for a non-marketed product so far this year, AstraZeneca PLC has paid Moderna Therapeutics Inc. (messenger RNA therapeutic development for various diseases) $240mm for options to develop and sell up to 40 new cardiometabolic, renal, and cancer compounds based on Moderna’s messenger RNA Therapeutics technology.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ pays $240mm up front for mRNA collaboration with Moderna
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice